Ligand--receptor interactions are customarily described by equations that apply to solutes, i.e. molecules that are homogeneously distributed in a solvent and free to move therein. Yet, neurotransmitter receptors, channel-associated receptors and most of the hormone receptors are integral components of the cell plasma membrane. This not only creates an in-homogeneity in the receptor distribution but, above all, it may profoundly affect the molecular and kinetic characteristics of their interaction with ligands provided that these are sufficiently lipophilic. Over the past forty years, experts belonging to disciplines like biophysics, biochemistry, pharmacology, biology and chemistry have contributed to a better knowledge of how membranes may affect ligand--receptor (as well as substrate--enzyme) interactions at the molecular level. The ambition of this review is to integrate the outcomes of these studies in a single comprehensive monograph and, by doing so, to stimulate interdisciplinary cross-talks on this far from obsolete topic.

1. Diffusion !
==============

Diffusion plays an eminent role in biology. From the microscopic viewpoint, it reflects Brownian motion; i.e. random walks of molecules in solution resulting from their continuous collisions with molecules of the solvent such as water. After statistical treatment, the behavior of a large set of such random walks can be formulated by the classical equations of macroscopic diffusion first introduced by Adolf Fick in 1855. *In vivo* as well as in appropriate surrogate *in vitro* experimental systems, such soluble molecules (solutes) will occasionally collide with the obstructions like cell membranes and the extracellular matrix. In the early mathematical treatments, cell membranes were considered to constitute perfectly reflective barriers so that solutes should bounce-off immediately after such a collision. Such calculations revealed that, after this first collision, it is most likely for solutes to collide with that surface more than once again before drifting away to the bulk of the solution ([@bib13]).

Most receptors for natural messengers like hormones and neurotransmitters are embedded in the cell plasma membrane and their interaction with these messengers or related ligands is customarily described by equations that apply to the interaction between two solutes, i.e. molecules that are homogeneously distributed in and free to move in solution. Yet, because of the comparatively enormous size of cells and even of isolated membrane fragments thereof, it is only the diffusion of the ligand molecules that needs to be taken into account. Moreover, since most of the receptors only cover a minute fraction of total surface of a cell plasma membrane, a direct hit between a free ligand and such receptor is probably a rare event. In their pioneering calculations on the influence of surfaces on heterogeneous reactions, [@bib13] concluded that it is most likely for the ligand to make a few encounters with non-specific areas of the membrane (which was considered to represent a reflective surface) before it interacts with an embedded receptor target or drifts away ([Fig. 1](#fig1){ref-type="fig"} , left panel). Because of this initial tendency of the ligand to remain in close proximity of the membrane surface, it has a higher probability to hit a receptor within a given time-span as compared to the situation in where both ligand and isolated receptor molecules are homogeneously distributed and freely diffusing in solution ([@bib13]). In other words, merely based on their physical characteristics, membranes are already able to boost the rate of ligand--receptor encounters. Of note is that, in those as well as in many ensuing calculations, receptors were represented as traps/"perfect sinks": i.e. somewhat similar to the holes in a snooker table, each hit with a receptor should result in the immediate and irreversible disappearance of the ligand molecule in question.Fig. 1Representative example of the path taken by a ligand to reach its receptor target at the surface of a membrane (black dot) via an exclusive 3D approach (left panel) or via a mixed 3D--2D approach (right panel) ([@bib83]).

In practice, cell membranes are able to undergo electrostatic and hydrophobic interactions with solutes. In many instances, small ligand molecules and even peptides become absorbed to the membrane--solution interface and in the case of highly hydrophobic ligands, they can even become completely embedded within the membrane ([@bib69], [@bib34]). Hence, the behavior of membranes is quite distinct from that of perfectly reflective barriers. Based thereon, [@bib1] first introduced the idea that the rate by which a membrane-associated traps reacts with a dissolved ligand can be enhanced if the ligand first absorbs to the surface of the membrane and then laterally diffuses to this "trap". This "reduction of dimensionality" theory implies that, rather than approaching the receptor by pure three-dimensional (3D) diffusion, the ligand should first be directed by 3D diffusion to a "non-specific" region of the membrane surface followed by its adsorption and further two-dimensional (2D) diffusion at the surface of or even within the membrane to the receptor ([Fig. 1](#fig1){ref-type="fig"}, right panel). These considerations obviously imply that the ligands in question should be able to perform their final approach to the receptor by a 2D route, i.e. without the need for temporarily leaving the lipid bilayer to reach the receptor from within the aqueous phase.

Conclusive evidence for 2D surface diffusion to a receptor target has been provided by patch clamp experiments with dihydropyridine (DHP) derivatives on cultured rat myocardial cells and neonatal rat or adult guinea pig ventricular cells. It was indeed shown that, when added to medium outside the patch, some of these ligands are anyhow able to affect single calcium channels within the patch ([@bib44], [@bib16]). Since the receptors make part of calcium channels that are physically isolated from the bulk solvent (i.e. because of their presence within the patch), the DHPs have to reach these receptors through the lipid bilayer instead of an aqueous 3D approach. Moreover, and in agreement with a thermodynamically highly unfavorable "flip-flop" of amphiphilic molecules between both leaflets of the plasma membrane, ionized DHPs only interacted with the calcium channel when applied from the correct side of the membrane ([@bib11]).

The major outcome of Adam and Delbrück\'s calculations was indeed that, on average, such mixed 3D--2D approach should allow the ligand to reach the receptor by a shorter route than in the case of an exclusive 3D approach. Based on the consideration that this increases the efficiency of multimolecular reaction processes at low concentration, [@bib27] went even one step further by suggesting that "reduction of dimensionality" is a nature\'s trick to overcome the barrier of diffusion control. This could explain the prevalence of membrane-bound enzymes in living systems.

Subsequent calculations were done with the aim to find out under which conditions "reduction of dimensionality" has the most favorable impact on the collision rate between a ligand/substrate and its membrane-associated receptor/enzyme. In this respect, the most important parameters to be taken into consideration were the ligand concentration in solution, the receptor concentration (i.e. amount of receptors per unit of membrane surface area), the distribution pattern of the receptors (such as homogenous dispersion *vs.* their accumulation in discrete areas such as lipid rafts), the 3D and 2D diffusion rate constants of the ligand (denoted by *D* ~3~ and *D* ~2~ respectively), the ligand\'s affinity for non-specific/non-target sites at the membrane and occasionally also the corresponding non-specific adsorption and release rate constants of the ligand. In general, the capture rate (i.e. steady-state flux of adsorbed ligands to the receptors/traps) via the combined 3D--2D pathway was found to increase upon increasing the ligand\'s affinity for non-specific sites at the membrane (given by the equilibrium dissociation constant *K* ~eq~, in moles l^−1^ of aqueous solution) and the surface diffusion coefficient *D* ~2~. In this respect, it is noteworthy that the ligand does not need to possess overly high affinity for the membrane to favor the combined 3D--2D approach ([@bib13], [@bib83]). For example, the relatively low affinity of ACTH~1--24~ for non-specific sites at the membrane (*K* ~eq~ of 40 μM) was calculated to be already strong enough to increase the speed/likelihood of this ligand to find a receptor upon switching its route from a 3D random diffusion in solution to a 2D search within the plane of the membrane ([@bib69]). Moreover, a two-step searching was also found to yield a rate advantage in the case of low bulk ligand and receptor target concentrations ([@bib1], [@bib13], [@bib64], [@bib54], [@bib83]). For example, because of the very low DHP receptor density in cardiac sarcolemmal membranes (i.e. 1 site/μm^2^), [@bib64] calculated that the mean time for ligand--receptor collisions via 3D--2D combination should be about 1000 times smaller than the mean time for collisions via the 3D pathway only.

2. Diffusion?
=============

Yet, because of differences in the models and in the restrictive assumptions, the calculations did not always yield the same outcome ([@bib83]). This led some to proclaim that there is no strict guarantee for a ligand to find a membrane-associated receptor more quickly with the aid of surface diffusion, even when *D* ~2~ is nearly as high as *D* ~3~ and when the ligand possesses moderate affinity for the membranes ([@bib54]). In this respect, 2D diffusion rates of small molecules may vary widely: from 1000 × less than the 3D rate for a fluorescently labelled β-adrenoceptor antagonist in membranes to as high as the 3D rate for molecules which diffuse in the central (most disorganized) part of artificial membranes ([@bib54]). An additional caveat with most of these models is that they only paid attention to diffusion-limited ligand--receptor interactions and that, to facilitate calculations, the receptors were regarded to act as irreversibly absorbing perfect sinks. A distinctive feature of a perfect sink is that, even in steady state, it induces a local depletion of soluble ligand molecules around itself ([@bib8]). Yet, this assumption does not fit with experimental findings indicating that receptors usually bind their ligands in a reversible fashion, releasing them unaltered back into solution. This implies that local depletion zones rarely exist under steady state conditions and, hence, that "perfect sink" models do not accurately describe real-world situations ([@bib83]).

An even more important conceptual turning point was provided by [@bib64]. These authors noticed that experimental DHP--receptor association rates were far lower than the ones calculated on the basis of diffusion only. It was therefore concluded that the binding of such ligands is reaction limited (reflecting the small probability of a diffusive ligand--receptor encounter to result in successful binding) rather than merely diffusion limited. Subsequent to these observations, [@bib8] explored the outcomes of a model in where collision with a ligand only rarely leads to binding and in where receptors do not create significant local depletion zones of the ligand. Quite similar to the outcomes of the previous calculations based on "perfect sink" models, it was shown that "reduction in dimensionality" could exhibit significant rate enhancement when the drug concentration in solution and *K* ~eq~ are low, *D* ~2~ is large and the receptor targets are far apart.

The relative contribution of ligand diffusion and the probability of successful binding to the formation (and dissociation) of bimolecular ligand--receptor complexes is addressed in a comprehensive model first introduced by DeLisi and coworkers ([@bib25], [@bib26]). This model stipulates that binding between a ligand (L) and its receptor (R) proceeds according to a two-step process. Diffusion of the ligand will first bring them to within a very short distance of one another (to the so-called "reaction distance") and it is only when this "encounter complex" (\[L...R\]) is formed that the binding process (formation of L·R) can take place with a specific "reaction forward rate constant" (*k* ~1~) ([Fig. 2](#fig2){ref-type="fig"} , left panel). This model neatly separates the ligand--receptor binding in two parts: one depends on the viscosity of the medium (manifested by the diffusion rate constants *k* ~+~ and *k* ~−~) while the other depends on the reaction mechanism (manifested by *k* ~1~ and *k* ~−1~). It can also be represented by a single-step process with the "effective" forward rate constant *k* ~f~  =  *k* ~+~ *k* ~1~/(*k* ~−~  +  *k* ~1~) and the "effective" reverse rate constant *k* ~r~  =  *k* ~−~ *k* ~−1~/(*k* ~−~  +  *k* ~1~) ([Fig. 2](#fig2){ref-type="fig"}, right panel). Inherently, this model implies that the mixed 3D--2D approach could provide a rate advantage over the 3D approach if partitioning of the ligand in the membrane allows it to adopt a more adequate position, orientation and/or conformation ([@bib64], [@bib18]). These issues are addressed in more detail below.Fig. 2Schematic representation of drug (L)--receptor (R) binding with the formation of an ephemeric encounter complex from where the drug can either bind with the reaction forward rate constant *k*~1~ or diffuse away from the receptor.

3. Ligand partitioning and penetration into the membrane
========================================================

When obtained after equilibrating the ligand between the aqueous solvent (buffer, medium) and membrane fraction, the equilibrium partition coefficient, *K* ~p~, can be calculated by dividing the ligand concentration in the membrane (in moles l^−1^ of membrane) by the ligand concentration in the solvent (in moles l^−1^ of solution). *K* ~p~ is dimensionless and should not be confused with the ligand\'s equilibrium dissociation constant *K* ~eq~ for binding to non-specific sites in the membrane. With respect to the experimental models that are used to estimate *K* ~p~ values, it is now widely accepted that partitioning of ligands in biological membranes and artificial phospholipid bilayer systems is more adequate than the previously widely used isotropic two-phase bulk solvent systems such as the octanol/buffer combination. Indeed, these latter experiments only provide information about the hydrophobicity of the ligand without taking account of the ability of the ligands to interact with the polar head groups of membrane lipids ([@bib51]). In line with this theoretical consideration, partition coefficients of DHPs and D~2~-dopamine receptor antagonists for membranes and membrane lipids are very different from those reported for the octanol/water combination ([Fig. 3](#fig3){ref-type="fig"} ) ([@bib60], [@bib51]). However, when using synthetic membranes for *K* ~p~ determinations, one also needs to be aware of the important contribution of their physical state (and e.g. the influence of the temperature thereon), their phospholipid composition and even their cholesterol content ([@bib50]). For example, the *K* ~p~\'s for DHP incorporation into lipid bilayers were found to be inversely related to their cholesterol content ([@bib35]).Fig. 3Dihydropyridine partition coefficients into biological (sarcoplasmic reticulum) membranes and octanol: adapted form [@bib51].

When *K* ~p~ is elevated, it is conceivable that the high concentration of ligand molecules in the membrane plays a more eminent role in boosting its rate of receptor association (i.e. the association rate constant multiplied by the local ligand concentration) than the faster accessibility of the receptors by 2D diffusion ([@bib51]). In other words, even if 2D diffusion is essentially nonexistent, increasing the local ligand concentration by membrane partitioning could produce a rate advantage compared to a pure 3D approach. In the same line, high affinity binding could merely be the consequence of an elevated concentration of ligand in the membrane ([@bib68]). Indeed, conventional equilibrium dissociation constants for ligand--receptor interaction (*K* ~D~, expressed in moles l^−1^ of aqueous solution) could be defined as $K_{\text{D}} = {K^{\prime}}_{\text{D}} \cdot K_{\text{p}}^{- 1}$ where ${K^{\prime}}_{\text{D}}$ is the local equilibrium dissociation constant ([@bib51], [@bib17]).

However, *K* ~p~-based calculations would still underestimate the true concentration of a ligand in the vicinity of the receptor if the ligand molecules were confined to a discrete portion of the bilayer ([@bib51]). Whatever the pertinence of this assertion, it points at a crucial aspect of membrane partitioning, namely that because of the highly ordered structure of the lipid bilayer, amphiphilic and lipophilic ligands align themselves within a membrane bilayer in a preferred orientation and location in accordance to their electronic and stereochemical properties. Hence, the physical characteristics of these ligands may contribute to the discrete depth by which they tend to reside within the membrane. This depth has been defined as the center of a Gaussian curve reflecting the distribution profile of the drug in the lipid bilayer ([@bib51]). That this location may affect *K* ~p~ is suggested by a comparative study by [@bib34] ([Fig. 4](#fig4){ref-type="fig"} ) in where (a) amiodarone was found to be located deep within the bilayer close to the end of the phospholipid fatty acid tails at the bilayer center and to have the highest *K* ~p~ value and (b) propranolol and nimodipine (a DHP) were closer to the hydrocarbon core--water interface of the bilayer and exhibited smaller *K* ~p~ values. This location facilitates both a hydrophobic interaction with the phospholipid acyl chains and electrostatic interactions between the amino functions of the ligands and the phosphate head groups.Fig. 4Locations of a membrane-spanning protein (hydrophobic TM domains are shaded) and the ligands amiodarone, nimodipine and propranolol at different depths within the lipid bilayer (from [@bib34]).

Based on observations that hydrophobic and amphiphilic ligands tend to reside at a discrete depth within the membrane, it has been proposed that the binding domains on their receptor should face the bilayer at the same "depth" as the active portion of those ligands ([@bib64], [@bib18], [@bib17]). In line with this view, structure--activity relationship and mutation studies suggest that the DHP binding site is located on the α-helical transmembrane (TM) domains of the L-type calcium channel approximately 11--14 Å from the external membrane surface ([@bib11]). This site is located allosterically with respect to the calcium-binding site of the channel ([@bib62]).

4. Lateral translocation between the receptor\'s transmembrane α-helices?
=========================================================================

Mutation experiments with G protein-coupled receptors (GPCRs) have pointed out that their binding pocket for small natural messengers and small competitive ligands is deeply embedded within the central cleft formed by their seven membrane-spanning α-helical domains (TM domains). Whereas such binding pockets are traditionally considered to be accessible to hydrophilic ligands that reside in the aqueous phase, it has already been proposed at several occasions that membrane-associated amphiphilic and lipophilic ligands could still gain access to them via lateral diffusion between the receptor\'s α-helical TM domains of that receptor ([Fig. 5](#fig5){ref-type="fig"}A). Such pathway has been proposed for a number of ligands ([Fig. 5](#fig5){ref-type="fig"}B) like the endogenous CB~1~ cannabinoid receptor agonist anandamide, the synthetic β~2~-adrenergic receptor agonist salmeterol, the AT~1~-type angiotensin II receptor antagonist losartan and the D~2~-dopamine receptor antagonist spiperone ([@bib4], [@bib5], [@bib76], [@bib85], [@bib53], [@bib52], [@bib77], [@bib61]). Anadamantine ([Fig. 5](#fig5){ref-type="fig"}B) is not stored in a cellular compartment but is produced upon demand from cell membrane phospholipid components. It is then conveyed by specialized carrier proteins to presynaptic nerve terminals where it incorporates in the plasma membrane. In these membranes, anadamantine is likely to adopt an extended conformation with its head group near the lipid--water interface and the end of its fatty acid tail near the bilayer center ([@bib12], [@bib48]). This allows anandamide to engage the CB~1~ receptors through a fast lateral diffusion within the membrane ([@bib52], [@bib77]). In this respect, a bXXb motif (formed by beta branching amino acids, V6.43 and I6.46) on the lipid face of the CB~1~ receptor in its inactive state has been proposed to serve as an initial interaction site for anandamide ([@bib77], [@bib49]). The fatty acid tail of this agonist is indeed located at the correct depth in the bilayer to interact with this motif. Other cannabinergic compounds are generally amphiphilic in nature as well and, although they are likely to bind to distinct pockets of the CB~1~ receptor, they are also thought to reach those pockets by lateral diffusion within the membrane ([@bib84], [@bib58], [@bib52], [@bib77], [@bib63], [@bib49], [@bib43]). Interestingly, a survey of sequence data by [@bib49] indicates that a matching bXXb motif is also borne by several other GPCRs for lipid-derived ligands like the CB~2~ cannabinoid receptor, an oxoeicosanoid receptor and several lysosphingolipid and prostanoid receptors.Fig. 5Panel A, proposed model in where hydrophilic ligands approach a GPCR from the aqueous phase while amphiphilic/hydrophobic ligands approach the receptor by lateral diffusion within the membrane and then translocate via the receptor\'s TM domains to their central binding pocket (TM domain in front of translocation is semi-transparent). Panel B, structure of amphiphilic ligands that allegedly reach their receptors via a combined 3D--2D approach. Panel C, binding of salmeterol via its hydrophobic phenylalkoxyalkyl tail to an alleged exosite in the vicinity of the β~2~-adrenergic receptor with occupancy (right side) or not (left side) of the receptor\'s central binding pocket by the saligenin head (TM domains in front of the saligenin head are semi-transparent). Panel D, binding of a lipid-conjugated gastrin molecule to its receptor according to a molecular modeling study by [@bib47] (TM domains in front of the peptide section are semi-transparent).

Salmeterol ([Fig. 5](#fig5){ref-type="fig"}B) is an amphiphilic synthetic β~2~-adrenergic receptor agonist. It consists of a hydrophilic saligenin head which is responsible for receptor activation and an extended lipophilic phenylalkoxyalkyl side chain which is responsible for its very high partitioning in synthetic membranes ([@bib65], [@bib14]). Similar to phospholipids, salmeterol is about 25 Å long, it assumes the same specific orientation in membranes and it is not prone to 'flip-flop' to the other face of the membrane ([@bib65], [@bib39]). This agonist is considered to accomplish a 2D approach as well as a lateral diffusion between the receptor\'s TM domains ([@bib39], [@bib5], [@bib21], [@bib75]). As only the hydrophilic saligenin head is necessary for receptor activation, it has been proposed that the phenylalkoxyalkyl side chain interacts with a non-polar region in the cell membrane in the close vicinity of the receptor, the 'exosite' ([@bib39], [@bib20]). This should allow the saligenin head to freely reach (and leave) the central core of the β~2~-adrenergic receptor by a Charnière (hinge) principle ([Fig. 5](#fig5){ref-type="fig"}C). This model provides also an elegant explanation for the very fast termination of the salmeterol response in the presence of hydrophilic antagonists like sotalol and the fast reappearance/"'reassertion" of the response when the antagonist is washed away even though no the wash-out medium is salmeterol-free ([@bib10], [@bib45], [@bib82]). The oxygen atom in the alkyloxalkyl side chain has been proposed to act as the point of support for the pivoting saligenin head ([@bib41]) and, in this respect, structure--activity relationship studies have pointed at an important role of its position in the alkyloxalkyl side chain. It has therefore been proposed that the efficiency of the saligenin head pivoting/docking process is dictated by the average depth of the "hinge" in the membrane ([@bib35], [@bib18], [@bib51], [@bib17]).

The combined 3D--2D approach has to do with ligands that are able to perform their final approach to the receptor without the need for temporarily leaving the lipid bilayer. Yet, this also applies to ligands whose reactive groups need to approach the receptor from the aqueous phase provided that another portion of these molecules is still tethered to the membrane ([@bib7]). This has been elegantly demonstrated with experiments involving fatty acid attachment to peptide hormones and analogues like CCK-9, \[Thr^28^,Nle^31^\]-CCK-(25-33) and \[Nle^15^\]-human-gastrin-(2-17) ([@bib67], [@bib55], [@bib57]). Starting with short lipid chains, initial elongation decreased the affinity of these lipo-gastrin peptide constructs for their respective receptor. As these lipid chains are still too short to permit a firm attachment of the construct to the membrane, they were still supposed to escape from the membrane first and then to reach the receptor\'s binding site via the aqueous phase. Hence, the effect of initial lipid chain elongation on the affinity of the constructs was related the fact that it became more and more difficult for them to escape from the membrane. However escape is no longer possible with lipid chain lengths beyond C10. This explains why further chain elongation no longer produced a substantial decrease in receptor affinity. These latter findings suggest that the extracellular loop domains of the involved GPCRs are sufficiently flexible and mobile to permit a lateral penetration of the peptide head groups at the water/lipid interface so that they can reach their binding site in the central cleft of the receptor ([Fig. 5](#fig5){ref-type="fig"}D) ([@bib47]). This also implies that if a segment of a peptide is sufficiently hydrophobic in character, it is likely to provoke the spontaneous partitioning of that peptide in the membrane ([@bib69]). Hence, the combined 3D--2D approach could also apply to certain peptide ligands.

5. Conformational modification of the ligand in the lipid bilayer
=================================================================

The so-called 'non-specific' nature of ligand--membrane interactions is likely to be a misconception. Indeed, rather than merely controlling ligand approach kinetics and local accumulation at the plasma membrane, these interactions could also affect the receptor binding process by exerting translational, conformational and orientational constraints on each ligand on a very specific structural basis ([@bib68], [@bib65], [@bib70], [@bib9]). In this respect, it is noteworthy that this not only applies to small amphiphilic ligand molecules but also to peptide messengers like gastrin, CCK and NPY ([@bib9], [@bib17], [@bib74]). While such regulatory peptides have no unique 3D structure in solution, they acquire well-defined conformations upon interacting with the membrane ([@bib69], [@bib22]). Hydrophobic interactions certainly play an important role in this process and for peptides it is generally assumed that amino acids with hydrophobic residues form alpha helices that penetrate perpendicularly into the lipid bilayer ([@bib32], [@bib68], [@bib15]). In the same line, ACTH~1--24~, substance P and dynorphin~1--13~ have been found to adopt a partially helical structure in 2,2,2-trifluoroethanol, a solvent that mimics the lipid environment ([@bib31], [@bib28], [@bib69]). Yet, peptide--membrane interactions could also comprise an important electrostatic component. This has clearly been demonstrated in the case of peptideSARSIFP (severe acute respiratory syndrome coronavirus sequence, amino acids 873--888), which interacts differently with the membrane depending on the charge of the phospholipids ([@bib15]). In the same line, the 39--42 amino acid long amphiphilic amyloid-β peptide (Aβ), the main constituent found in extracellular amyloid plaques in the brain of Alzheimer Disease patients, is likely to be inserted in the plasma membrane by its hydrophobic domain prior to its release. In this respect, experiments with Aβ1--40 revealed that only a short part of this peptide is inserted in neutral lipid bilayers ([Fig. 6](#fig6){ref-type="fig"}A). This is because the hydrophilic part of these peptides is only stabilized in the bulk solution. However, the insertion becomes more pronounced upon increasing the membrane surface potential because of the emerging electrostatic anchoring of charged peptide residues close to the membrane surface ([@bib15]).Fig. 6Panel A, insertion of the hydrophobic Aβ1--40 peptide segment into membranes ([@bib15]). Panel B, simplified scheme for the "membrane catalysis" model of [@bib68] in where partitioning and conformational change of a peptide ligand is described as a single equilibrium step defined by *K*~p~. ${K^{\prime}}_{\text{D}}$ is the local equilibrium dissociation constant and refers to the ligand concentration in the membrane at which half of the receptors are occupied. The overall equilibrium dissociation constant for the ligand--receptor interaction (*K*~D~, expressed in moles l^−1^ of aqueous solution) corresponds to $K_{\text{D}} = {K^{\prime}}_{\text{D}} \cdot K_{\text{p}}^{- 1}$.

Electrostatic and hydrophobic components of the ligand--membrane interaction may produce a favorable enthalpic contribution capable of compensating the entropic penalty resulting from the reduced number of conformations and orientations that the ligand can adopt within the membrane ([@bib69], [@bib56]). Provided that some of the conformations and orientations of the membrane-associated ligand are favorable for receptor binding, this process will have less entropy requirements. In other words, there should be an entropic advantage for the 2D approach when compared to a situation in which the ligand approaches its binding site at the receptor via a 3D random walk in solution ([@bib17]). An interesting aspect of dividing the binding process in several steps is that, compared to a one-step model with equivalent total free energy (Δ*G*  ≈ observed *K* ~D~), the lower energetic requirements of the individual steps should significantly increase the overall reaction rate ([@bib68]). For the same reason, there should also be a significant increase in the overall dissociation rate, implying that ligands with experimental equilibrium dissociation constants of 1 nM may have dissociation half-lives in the minute range. These considerations constitute the rationale for the "membrane catalysis" model ([@bib70], [@bib68]), which stipulates that a flexible peptide ligand binds to the membrane in the first step. After acquiring a membrane-induced conformation, the peptide then binds to the receptor in the second step ([Fig. 6](#fig6){ref-type="fig"}B). According to this view, the most important role attributed to membranes is their ability to optimize the conformation of the peptide ligands, so that they enter and fit the binding site of the receptor with greater ease. The membrane catalysis model is obviously also applicable to non-peptide ligands but, irrespective of the ligand, it is only applicable if the receptor possesses a docking site at the required depth in the lipid bilayer and if the ligand acquires a binding-prone conformation in the membrane ([@bib2], [@bib17]).

The membrane catalysis model is supported by several experimental observations. For example, side chain deployments in the membrane-bound state of substance P analogues are found to be similar to those in the biologically active chemically constrained states ([@bib70]) and peptide hormones such as glucagon, ACTH, calcitonin, and β-endorphin also have amphiphilic structures that are essential for biological activity ([@bib42]). On the other hand, \[L-Ala^2^\]Leu-enkephalin may be inactive because its orientation on membranes is different from that of the active compounds ([@bib70]).

6. Ligand partitioning and *in vivo* residence time
===================================================

In drug screening studies the interaction between a receptor and its ligands is traditionally quantified in terms of affinity only. Yet, there is increasing awareness that the *in vivo* effectiveness and duration of ligand action is also dictated by the time period over which this ligand resides at its receptor ([@bib24], [@bib78], [@bib80]). This *in vivo* residence half-life should not be confused with the half-life by which ligand--receptor complexes dissociate. Indeed the half-life of the ligand--receptor complexes is measured under conditions in which no new complexes can be formed, e.g. by adding an excess of unlabelled ligand in the case of radioligand dissociation experiments ([@bib81]). Instead, the *in vivo* residence half-life refers to the time needed to halve the receptor occupancy when the concentration of free and membrane-associated ligand is more or less slowly declining (via desorption, clearance, degradation,...). This implies that, at any time, complexes can still be formed by binding of native ligand molecules as long as they are still around as well as by rebinding of ligand molecules that previously dissociated from the same or neighboring receptor molecules ([@bib81]). In this respect membrane partitioning could contribute to a long residence time by a number of different mechanisms.

From an equilibrium point of view, very lipophilic molecules have a high membrane/water partition coefficient *K* ~p~ because they prefer to reside in the lipid bilayer hydrocarbon core. Without considering other parameters, the accumulation of such ligands in the membrane may already increase their *in vivo* residence half-life because of the hyperbolic relationship between the free ligand concentration and receptor occupancy (such as shown by a typical radioligand saturation binding curve). This implies that, when starting with an already low free ligand concentration (i.e. when only part of the receptors are occupied), the *in vivo* residence half-life will be very close to the half-life by which the free ligand concentration declines ([Fig. 7](#fig7){ref-type="fig"}A). However, when the initial ligand concentration is elevated (i.e. when most of the receptors are occupied), the *in vivo* residence half-life will markedly exceed the half-life of the free ligand.Fig. 7Panel A, influence of the initial receptor occupancy (abscissa, in percent of total receptor concentration) on the residence half-life (ordinate, the free ligand half-life being taken as unit) when the free ligand concentration decreases exponentially with time. Panel B, a high *K*~p~ and a slow ligand desorption rate act in concert to prolong the concentration of a membrane-associated ligand within the therapeutic window (adapted from [@bib35]).

While *K* ~p~ refers to the ratio of the adsorption and release/desorption rates of a ligand, it is obvious that these pharmacokinetic parameters may also affect the ligand\'s therapeutic action in their own right. In this respect, slow release from the plasma membrane is widely considered to play a preponderant role in the long duration of action of highly lipophilic ligands. This is typically illustrated by the hydrophobic β~2~-adrenergic receptor agonist salmeterol ([Fig. 5](#fig5){ref-type="fig"}B) whose aptness to produce pseudo-irreversible relaxation of guinea pig trachea and human bronchi at all concentrations ([@bib39], [@bib59]) has been linked by some to its slow release from airway smooth muscle membranes ([@bib4], [@bib5], [@bib6]). Such link is embodied in the "diffusion microkinetic" model that stipulates that the plasma membrane can act as a depot/reservoir for the ligand rather than merely functioning as an inert substratum for the receptor ([@bib3], [@bib21]). Obviously, slow desorption will act in concert with a high *K* ~p~ to prolong the effect duration of a ligand ([Fig. 7](#fig7){ref-type="fig"}B). This has been proposed to be the case for the highly lipophilic DHP lacidipine ([@bib35]). Lacidipine has a higher *K* ~p~ than many other DHPs (so that a higher local concentration can be attained), it is located deeper in the lipid bilayer and it partitions slower into and out of the membrane. While the high *K* ~p~ establishes a high concentration of this ligand within the membrane, it slow release ensures that its concentration in the membrane remains above its therapeutic threshold for a long period of time ([@bib35]). This combination of properties may explain the comparatively gentle onset and long duration of clinical action of this drug despite its short plasma half-life ([@bib35]).

However, membrane partitioning could also increase the effect duration of a ligand by alternative mechanisms. An intriguing possibility is that some ligands could undergo specific and long-lasting binding to 'exosites' in the membrane. These auxiliary sites could be located either at the receptors themselves (i.e. an anchoring site that is different from the active site but is not supposed to affect the conformation of the active site via an allosteric mechanism) or in their immediate vicinity in the membrane. The exosite theory was originally proposed by [@bib66] to explain the persistent antagonistic activity at histamine H~1~ receptors and it has subsequently been adopted to explain the long duration of action of the muscarinic acetylcholine receptor agonist xanomeline and the β~2~-adrenergic receptor agonist salmeterol ([Fig. 5](#fig5){ref-type="fig"}C) ([@bib39], [@bib40], [@bib21], [@bib19]). The presence of an exosite implies that, once dissociated from the active site of the receptor, the ligand is not free to diffuse away from that receptor. This constitutes an important difference with the microkinetic theory that permits ligands to freely interchange between the receptor\'s active site and the lipid bulk phase. Hence, while the concentration of free ligand should be prone to decline due to redistribution, degradation and/or other elimination pathways, the concentration of ligand available for active site binding should be maintained for a longer time period in the case of exosite binding ([@bib30]).

A major handicap of the exosite theory is that such auxiliary binding sites have hitherto never been positively identified (e.g. by radioligand binding studies) and that a number of experimental findings even cast doubt on the validity of this theory ([@bib14], [@bib75], [@bib37]). For example, it was argued that if the exosite for salmeterol displays pharmacological specificity and high affinity for its phenylalkoxyalkyl side chain, other molecules with the same side chain would attenuate its reassertion behavior of salmeterol. Yet such structural mimetics failed to do so ([@bib14]). Moreover, in disagreement with the exosite theory, reassertion of the muscarinic acetylcholine receptor agonist xanomeline only took place at high concentrations in cell systems and, in the same vein, persistent reassertion of the salmeterol-mediated relaxation of strips from guinea pig trachea was only observed when its initial concentration was sufficiently elevated ([@bib14], [@bib37]). This provides support to those who claim that the reassertion of an agonist\'s effect is simply related to its long-lasting association with the plasma membrane (i.e. the 'microkinetic' theory). The term "reassertion" has hitherto only been linked to the reappearance of an agonist\'s effect. Yet, this term could apply to all ligand types if, by definition, it refers to the reestablishment of receptor occupancy (rather than solely receptor activation) by a ligand after wash-out of the aqueous ligand-containing solution and temporary occupancy of the receptor\'s binding pocket by a competitive ligand molecule. Based on this more general definition, "reassertion" is likely to apply all kinds of amphiphilic/hydrophobic ligands. In this respect, it could well explain some of the behavioral aspects of D~2~-dopamine receptor antagonist \[^3^H\]-spiperone in radioligand binding studies on intact recombinant cells ([Fig. 8](#fig8){ref-type="fig"}A).Fig. 8Panel A, translocation of \[^3^H\]-spiperone from "non-specific" sites in the plasma membrane from recombinant intact Chinese hamster ovary cells (CHO cells) to the therein-expressed D~2L~-receptors. Experiments were done as in [@bib61]. In short, intact cells were pre-incubated for 30 min at 37 °C with 1 nM \[^3^H\]-spiperone after which its specific (i.e. 1 μM (+)-butaclamol-displaceable) binding is measured (here denoted as control binding). Co-addition of 10^−5^ M raclopride reduces the \[^3^H\]-spiperone binding to 15% of the control (Lane 1). When \[^3^H\]-spiperone + raclopride-pretreated cells are washed twice (to remove the free ligands present in the aqueous solution) and finally incubated for 10 min at 37 °C with buffer alone, specific binding almost doubles (Lane 2). This increase reflects genuine receptor occupancy as it can be blocked by raclopride in a concentration-dependent fashion (10^−7^ M in Lane 3 and 10^−5^ M in Lane 4) and with the same potency as in competition binding experiments. *N* = 3--5. Panel B, different rates of \[^3^H\]-spiperone dissociation from D~2L~-receptors in recombinant CHO cells and membrane preparations thereof. Intact cells (♦) and membrane preparations thereof (●) were incubated for 30 min at 37 °C with 1 nM \[^3^H\]-spiperone. \[^3^H\]-Spiperone dissociation at 37 °C was initiated with 1 μM (+)-butaclamol and, at the times indicated, its remaining specific binding was measured. The same dissociation experiments were also done with leaky cells (■), i.e. in the throughout presence of 0.01 mg/ml of the pore-forming agent filipin. *N* = 3.

Finally, by retaining dissociated ligands to a compartment with a small volume such as a cell plasma membrane could favor their propensity to rebind/re-associate to the same or to neighboring receptor molecules. Such compartments could also include synapses ([@bib23]), tortuous paths with blind pockets are tissues such as the brain and even spaces between cells in a monolayer culture ([@bib36], [@bib73], [@bib79]). In radioligand dissociation experiments, this "rebinding" phenomenon leads to an apparent decrease in the radioligand\'s dissociation rate in wash-out medium only (i.e. when radioligand rebinding is possible) when compared to similar wash-out experiments in the presence of an unlabelled competing ligand at high concentration; i.e. when radioligand rebinding is effectively prevented ([@bib81]). Based on intact cell experiments, rebinding was recently shown to be so extreme as to approach virtual irreversibility in the case of the lipophilic D~2~-type dopamine receptor antagonist spiperone ([@bib61]) and the CB~1~-type cannabinoid receptor inverse agonist taranabant ([@bib71]). These experiments are compatible with the ability of cell membrane confinement to exacerbate rebinding phenomena with lipophilic drugs and, as suggested by recent simulation studies ([@bib71]), rebinding could explain the long-lasting effect of salmeterol as pertinently as the exosite model. In the same line, rebinding could also explain the need for the simultaneous presence of receptors and their lipid environment for the wash-resistant xanomeline binding to take place ([@bib38]).

Finally, while tortuosities in extracellular spaces in tissues could already limit the diffusion of molecules in general, the repeated partitioning in cell membranes is likely to further exacerbate this process in the case of hydrophobic ligands ([@bib46], [@bib36]). By retaining a hydrophobic ligand in its target tissue, repeated partitioning could greatly contribute to the often-observed long-lasting effect of such molecules *in vivo* as well as in *in vitro* experiments with intact tissues.

7. Concluding remarks
=====================

The so-called non-specific partitioning of amphiphilic/hydrophobic ligands in plasma membranes may exert control on their receptor binding characteristics in many ways such as by altering the time they need to reach a receptor molecule, their conformation and the receptor-domain towards which the final approach takes place. These effects, along with the accumulation of such ligands in a small volume around the receptors may affect their association rate, their affinity as well as their *in vivo* residence time at the receptor. However, general rules are hard to formulate, as membrane partitioning does not always exert a positive influence on the ligand\'s receptor binding characteristics. Novel membrane-connected concepts, including exosite binding and ligand translocation between the receptor\'s α-helical transmembrane domains have been advanced as well but, by lack of tangible proof, the physical reality of these concepts is likely to remain matter of debate for some time to come. In addition, new questions recently emerged such as why some antagonists display distinct receptor-binding kinetics in intact cell systems when compared to leaky cells and membrane preparations thereof ([@bib33], [@bib29], [@bib72]). An additional example thereof is shown in [Fig. 8](#fig8){ref-type="fig"}B. Further research in these areas (and about hydrophobic/amphiphilic ligand--receptor interactions in general) is highly desirable, especially because of the increasing awareness that receptor-binding kinetics may influence the *in vivo* effectiveness and duration of ligand action and, accordingly, that kinetic issues should also be addressed in screening studies.
